×

2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds

  • US 6,992,074 B2
  • Filed: 10/01/2004
  • Issued: 01/31/2006
  • Est. Priority Date: 05/31/2000
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of treating a metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of a compound selected from the group consisting of19-nor-2α

  • -ethyl-1α

    ,25-dihydroxyvitamin D3,19-nor-2β

    -ethyl-1α

    ,25-dihydroxyvitamin D3,19-nor-20(S)-2α

    -ethyl-1α

    ,25-dihydroxyvitamin D3,19-nor-20(S)-2β

    -ethyl-1α

    ,25-dihydroxyvitamin D3,19-nor-2(E)-ethylidene-1α

    ,25-dihydroxyvitamin D3,19-nor-2(Z)-ethylidene-1α

    ,25-dihydroxyvitamin D3,19-nor-2(E)-ethylidene-20(S)-1α

    ,25-dihydroxyvitamin D3,19-nor-2(Z)-ethylidene-20(S)-1α

    ,25-dihydroxyvitamin D3.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×